health corp expert
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wouldn't be the company or officers selling shares. That would be reported to the SEC and no insider sales have been reported.
Exactly what I was seeing. Could have picked up more than 100,000 shares at less than .08. What a great opportunity and incredible that this stock can be purchased as these low prices. Surely it won't be much longer before news that will start the stong upswing.
yes, agreed..no update and no news in months is killing this stock. At least when news does hit it should bring should reaction.
Seems to indicate a positive development. The 8k reports that 4 consultants are receiving options and that the CEO and the President and a another consultant who already had options are having their's modified with the change in exercise price---which likely is the option price for the 4 consultants. Suggests that consultants are doing something good for them. The best thing is that the CEO also funds the company. A Rarity in public companies and the best sign of confidence. And when you consider there have been no insider selling of stock in the past 2 years, this is really good stuff. Hope for some business development news soon. Should get this company on the map bigtime.
no news since April 5. News soon we hope
Good news. CMS came out with new stricter guidelines on resupply of recurring medical supplies, which includes glucose test strips, lancets, etc. Suppliers will have to know the patient's inventory level, rate of use, etc. to determine if they actually require additional resupply. The ALRT HeC system I belive provides all the information and documentation that suppliers will need. Pretty darn sweet. http://www.hmenews.com/article/providers-wary-re-supply-change
Wow, something is happening. Some one bought 147,000 shares after hours. At .07, but still, very impressive demand. Now maybe the low ball sellers will start seeing things a little different. Maybe next week will be a breakout?
agreed, a steady climb with no gapping
yeah, but someone keeps feeding the buyers at that low price. Surely those who are so willing to dump the stock at this low price will be bought out soon. Sure nice to see the buying demand though. Must be some smart people just now finding out about the potential of ALRT.
yes, it could take more time. Here is how I look at it. In the webinar ALRT reported cash flow per diluted share of $4.50--IF they had 4 million insulin dependent diabetes patients on the system. Given, it's software they sell the margins should be high thus I guess after tax earnings on that $4.50 at about $3.00 per diluted share. Then let's use a P/E of 30 (healthcare technology in a high growth newly developing field yields high P/Es). That brings the share price to $90. And insulin dependent is only 20% of all diabetes patients. And it's only US, does not include Europe, Asia, etc. And it does not include heart patients, respiratory patients, infectious disease, etc. Thus, the $90 per share would come about if they gain a mere 3% of their total market. So, a $5 share price can come about with a market share of less than 1%. That would take only about 200,000 diabetes patients to get it to the $5.00 share price. I would expect they could announce a deal with an insurance company or other before this fall that would represent that many patients or more. Sure will be exciting. Also, even with several competitors, ALRT could get to my 12 to 18 month target prices---and the $25 level looks very reasonable with these assumptions. DYODD
Well, given the diabetes population and the costs of care, and that the ALRT system does so much good in improving health outcome AND reducing costs, my target for this fall is $5 and $25 within 12 to 18 months. Take a look at the corporations that are well entrenched in diabetes management. Most have market caps above 50 billion. I think the ALRT HeC system has perfect timing for the health insurance companies, including medicare and all the state medicaids. Reduce costs while improving care!!
Yes, as mentioned last week, I contacted them. They of course cannot tell any individual any news that is not made public so they wouldn't reveal anything but my research tells me that all is well and may turn out even better than I've ever thought possible.......and I assure you I have had high targets with ALRT.
Research Report Updated by Investement Bank on ALRT. Target Price is $0.50. See the Taglich Brothers updated report on ALRT here. http://www.taglichbrothers.com/EquityUniverse/companies/alrtechnologies/alrtechnologies.aspx
janetjackson; I couldn't get the contact funtion to work either, but I called them. All is well. They obviously can't provide any news to an individual. The more I re-read the webinar presentation materials on their site and the Taglich research report and combine it with all the news in the healthcare industry I'm more bullish on ALRT than ever. Will be exciting when Taglich updates their target price after it blows through the .50 level.
I'll try and let you know. Yes, news is needed. Should be soon based on their webinar
Janetjackson: great opportunity right now to buy more at this rediculously low price. I suspect that the next news will be something much bigger and better than any of us would have guessed. So many healthgroups are looking at ways to improves cost efficiencies without reducing patient services......and the ALRT HeC system apparently does even better than that. The big insurance groups and Medicare and the state Medicaids should be all over this......and if they are already hopefully it's only a short time before we start seeing the news train on them.
ALRT with the FDA clearance and now with an investment bank issuing a research report and $0.50 target price is set for nice increase with next news release
ALRT with the FDA clearance and now with an investment bank issuing a research report and $0.50 target price is set for nice increase with next news release
ALRT with the FDA clearance and now with an investment bank issuing a research report and $0.50 target price is set for nice increase with next news release
Now with some news it looks primed to take off. Consider that the ALRT system can provide cost reduction to Medicare without reducing any services or benefits to the patients!!! And actually provides more services to the patients. The decision makers need to get going on this asap.
Lonewolf1, I stand corrected. Just noticed someone has lowered their ASK price and is offering 100,000 shares at that price, so those .06 and change bids just might get filled.
I don't see it being filled at that low of a price.
Janetjackson; I agree with sateliteguy on this: I've never not been able to buy or to sell, regardless of volume or price, when I'm put in low ask or high bid, etc, or hitting the bid or slapping the ask. Are you putting in orders of "all or none"? I do agree with you that it will reach $0.50 with just a nice volume run---but this volume run must be based on fundamental news of contract or CMS policy, etc. And then it should go much higher than that. I see this stock as one of the best opportunities out there.
Agree with you satelliteguy. There is very little volume moving. So no real demand developed yet. A few shareholders who need to sell, bring price down when there is no real demand. Demand will come as soon as the news gets out that ALRT suggested would in the webinar. And the analyst report discussed the likelihood of Medicare decision that will propel ALRT. One news event could generate buying in good volume. The low sellers will be bought up quickly.
Same with me. They stated in their webinar that they expected to be announcing contracts by late April to early May. So could be soon. But, I really expected the Taglich research report and target price to bring in buyers. Again, hopefully the buyers enter the market soon.
I'm afraid their business model is flawed. Margins are too low and total expense too high. Need new products with reasonable margins ... but also need demand.
Investment Bank is rating ALRT as Speculative Buy.
Analyst Research Report. Check this out. www.taglichbrothers.com
Scroll down the right side to see the place to click on research report they have done on ALRT. Taglich is covering ALRT. Very impressive research Report. And they rate ALRT as Speculative BUY. Initial target price of $0.50. Very reasonable as a first target level and surely will be updated often with ever increasing target prices. They would update as price increases and as milestones are reached such as the Medicare policy on electronic verification of use prior to reimbursement, etc.
Game On.
Investment Bank posts speculative BUY on ALRT
Analyst Research Report. Check this out. www.taglichbrothers.com
Scroll down the right side to see the place to click on research report they have done on ALRT. Taglich is covering ALRT. Very impressive research Report. And they rate ALRT as Speculative BUY. Initial target price of $0.50. Very reasonable as a first target level and surely will be updated often with ever increasing target prices. They would update as price increases and as milestones are reached such as the Medicare policy on electronic verification of use prior to reimbursement, etc.
Game On.
Analyst Research Report. Check this out. www.taglichbrothers.com
Scroll down the right side to see the place to click on research report they have done on ALRT. Taglich is covering ALRT. Very impressive research Report. And they rate ALRT as Speculative BUY. Initial target price of $0.50. Very reasonable as a first target level and surely will be updated often with ever increasing target prices. Game On.
Agreed. Huge Potential Reward with very little risk.
it will take announcement of a significant contract with a large healthcare group, Medicare actions and/or some state Medicaids. According to the ALRT webinar, they expect to be able to announce a contract by late April/early May. So we don't have much longer.
yes, very surprising..I expect its because very few investor type of people are aware of this company. Hope the word spreads to some investment banks, some brokerages, etc.
ALRT holds Webinar.Webinar posted.
ALRT holds webinar and posted.
Webinar posted.
Webinar was very interesting. They were very careful, as expected, about announcing any agreements with healthcare companies, insurance groups or govt. agencies. Of note, what they didn't say might have been a key..regarding questions about Medicare and Medicaid. I'm pumped from what I heard. Also, the slide and discussion about "possible" cash flow was heavy duty info. Said pre-tax cash flow of approx. $4.50 per share is potential from just the insulin dependent diabetics. This is a WOW factor. $4.50 cash flow should equate to a share price range of $90.00 to $120.00 a share. Of course, WHEN is the issue. But also consider this is only with insulin dependent diabetics.......does not include all the other 15 million plus diabetics, nor the other chroinic diseases which they said they would go after. A question about the ALRT HeC system becoming the WINDOWS of healthcare was brought out. I'm more positive than ever on the future.
I listened in for the entire discussion. Was good. Have to go out for a while. I'll give you a summary of my thoughts later this evening.
Investor Webinar today. Will be good to hear the update on developments. Maybe some stock buying today to get out ahead of the news. Following is the information on the investor registration site.
ALR Technologies, Inc. Investor Conference
Webinar Registration
ALR Technologies is pleased to provide its shareholders with an update on corporate developments for its proprietary Health-e-Connect system, an FDA-cleared chronic disease management technology approaching market launch for diabetes management. The meeting will be conducted from 4:30 PM EDT to 5:30 PM EDT on Monday, March 19, 2012. All questions during the meeting should be submitted by attendees in written format. The questions will be answered at the end of the presentation by Mr. Sidney Chan, CEO of ALR Technologies, Inc.
The meeting will be hosted by ALR Technologies CEO Sidney S. Chan and will include an investor presentation followed by a question and answer session.
Check this out from the Daily Beast.
http://www.thedailybeast.com/articles/2012/03/11/web-black-market-in-diabetic-supplies-costs-government-200m.html
ALRT very prominent.
Web Black Market in Diabetic Supplies Costs Government $200m
Mar 11, 2012 3:04 PM EDT
The government subsidizes $1 billion in medical supplies for diabetics annually, but due to illegal online resellers at least $200 million of that isn’t accounted for, Diane Dimond reports.
Last month, the federal government won its case against Gary Winner, the CEO of Planned Eldercare, an Illinois medical-supply company. Winner had been charged following an intensive investigation which found that his company preyed on older patients by asking for their Medicare number in return for free medical devices.
Many of Winner’s marks had diabetes, and he sent them what every diabetic needs: blood-testing strips and lancets, which they use to monitor their blood glucose levels—some of them several times a day. But Winner also threw in various ankle, knee, and elbow braces, and even erectile-dysfunction machines. According to court papers, Winner bought penis pumps from a California sex-toy shop, repackaged them and labeled them as medically necessary devices for diabetes to “help increase blood flow to the prostate.” Planned Eldercare then billed Medicaid at a 1000% markup, for a total of more than $370,000.
The prosecution of Winner, which resulted in a three-year-plus prison sentence for Medicare fraud, was a long time coming, but there is more that could be done to expose the darker corners of the multibillion-dollar business that is diabetic medical supplies.
Nearly 25 million Americans struggle with diabetes, and about 2 million are diagnosed with the life-threatening disease each year. The Centers for Disease Control reports diabetes is a major cause of heart disease and stroke, and the leading cause of kidney failure, new cases of blindness and a majority of limb amputations. In other words, it is not a disease to mess around with.
But that is happening every day, as uninsured diabetics, faced with the high cost of the blood-monitoring equipment, are increasingly turning to quasi-legal or outright illegal suppliers. At a pharmacy, a box of 100 small plastic blood-testing strips sells for about $125. On the Internet the price can be less than half that.
For example, a recent posting on Craigslist in Dallas, under the title “Contour Diabetes Test Strips,” offered “9 boxes ... unopened 50 strips per box. Asking $20 per box obo exp 6/2012”.
The posting, like most of its type, mentions nothing about how the seller got the boxes. The truth is that some are offered by family members of deceased diabetes patients, others by those who shoplifted the items from a store. Nationwide, entrepreneurs scout estate sales looking for abandoned supplies to resell online.
And even though no diabetic patient could possibly use 450 test strips by June, the demand for cut-rate supplies remains high, and the lack of significant federal regulation in the area makes it very difficult to stanch the supply. (Public health officials caution diabetics that the strips are sensitive to moisture and temperature, and are not reliable unless kept in a controlled environment and sold by a licensed pharmacist.)
In fact, the federal government itself may be an unwilling abettor to the fraud. Of the more than $1 billion that Medicare and Medicaid spend each year subsidizing purchases of test strips, at least $200 million of that is “unaccounted for,” according to a recent series of region reports by the Department of Health and Human Services. Privately, officials say that number is a very conservative estimate of the annual losses.
At a pharmacy, a box of 100 small plastic blood-testing strips sells for about $125. On the Internet the price can be less than half that.
When asked to comment on what is being done to alleviate the fraud and waste connected to the supply of government-subsidized diabetic supplies the Center for Medicare and Medicaid Services did not immediately respond to requests for comment.
While test strips and lancets are both available over the counter, any seller of diabetic supplies must register with the Food and Drug Administration. Some online merchants, such as charitable organizations, have done so, but most have not. And no online sales are sanctioned by the biggest manufacturers—Johnson & Johnson’s LifeScan brand, Abbott, Bayer, Nipro, and Roche.
So where are all the underpriced diabetic supplies coming from?
Shirley Mendoza, for one. In 2004, Mendoza was working as an administrative assistant at a Roche lab in Berkley, Calif., and somehow convinced the home office in Indiana to send thousands of boxes of test strips to the lab, where she intercepted them. Prosecutors said Shirley sold the strips on eBay for a total of $1.5 million, then funneled the money through her husband’s bank account to buy eight expensive cars and three properties. After a joint investigation by the FDA and the FBI the Mendozas were arrested and charged with conspiracy, mail fraud, and money laundering. Charges against her husband were ultimately dropped, but Shirley pleaded guilty and was sentenced to just under three years in prison.
A much bigger problem than individual fraud is the glut of supplies, which drives the online black market.
Jerry Koblin, who runs a family pharmacy in Nyack, N.Y., says many of his customers complain that their auto-fill programs send far too many boxes of test strips. Online resellers are aware that the strips expire, of course, and constantly run newspaper and Internet ads screaming, “WE BUY TEST STRIPS! $20-$30 FAST CASH!” For diabetics with an oversupply of strips, it is a tempting offer, even though it is against the law to resell supplies subsidized by Medicare or Medicaid.
Koblin says lower-income diabetics also sometimes make the difficult decision to pay for groceries instead of medical supplies. “Some patients who are supposed to test themselves three times a day may only test once, or skip a day here and there,” Koblin explained. “The leftover strips add up quickly.”
But the government is beginning to take more concrete steps to combat the waste and fraud in the diabetic-supply industry. The HHS will shortly release a consumer-fraud alert urging millions of diabetics on Medicare and Medicaid to report if they believe they have been the target of fraudsters offering “free” supplies through cold calls.
There are also technological approaches to reducing the amount of graft in the diabetes supply chain.
In October, Atlanta-based ALR Technologies got FDA approval for a new cross-platform technology that could remotely tap in to any blood-glucose monitor and forward its information to doctors, insurers or even the government.
Currently each of the major diabetes-monitor manufacturers makes a slightly different model that only reads their branded test strips. The monitors themselves are often treated as loss leaders, given away to encourage patients to buy the strips. But as a result, data stored in one monitor cannot be transferred to another, and it is difficult to tell how many test strips a patient has legitimately used in the monitor each month. That data is crucial in determining how many the patient needs in the future.
“The technology is readily available,” said Sidney Chan, the chairman and CEO of ALR. Chan and others familiar with the challenges diabetics face see electronic verification of test-strip usage as the best first-step solution to a multimillion-dollar problem. “The reason why it is not being used is that it has not been required by Medicare.”
“Diabetes is the most costly of all the chronic diseases to treat,” Chan said. “If the test supplies are used properly the patient has control over the disease. If they aren’t used correctly all of us pay for the full complications of it.”
Like The Daily Beast on Facebook and follow us on Twitter for updates all day long.
Investigative journalist and syndicated columnist Diane Dimond has covered all manner of celebrity and pop-culture stories. Her latest book is Cirque Du Salahi, which uncovered the full story behind Tareq and Michaele Salahi, the so-called White House gatecrashers. Dimond has written extensively about the John Edwards sex scandal for The Daily Beast, and she first broke the news that King of Pop Michael Jackson was under investigation for child molestation. She is the author of the book Be Careful Who You Love—Inside the Michael Jackson Case. She lives in New York with her husband, broadcast journalist Michael Schoen.
For inquiries, please contact The Daily Beast at editorial@thedailybeast.com.
Author
Diane Dimond
So ALRT will be informing us today of the date and time the Webinar will take place? Hopefully the webinar is early this week. With 5 different marketmakers placing sell offers at .12 or .11, I've given up trying to understand. Thats a lot of different market makers trying to sell at these low prices.Nothing surprises me anymore though.